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Abstract Recurrent chromosomal translocations associated
to peripheral T-cell lymphomas (PTCL) are rare. Here, we
report a case of PTCL, not otherwise specified (NOS) with the
karyotype 46,Y,add(X)(p22),t(6;14)(p25;q11) and FISH-
proved breakpoints in the IRF4 and TCRAD loci, leading to
juxtaposition of both genes. A 64-year-old male patient pre-
sented with mild cytopenias and massive splenomegaly.
Splenectomy showed diffuse red pulp involvement by a pleo-
morphic medium- to large-cell T-cell lymphoma with a CD2+
CD3+ CD5− CD7− CD4+ CD8+/− CD30− TCRbeta-F1+
immunophenotype, an activated cytotoxic profile, and strong
MUM1 expression. The clinical course was marked by dis-
ease progression in the bone marrow under treatment and
death at 4 months. In contrast with two t(6;14)(p25;q11.2)-
positive lymphomas previously reported to be cytotoxic
PTCL, NOS with bone marrow and skin involvement, this
case was manifested by massive splenomegaly, expanding the
clinical spectrum of PTCLs harboring t(6;14)(p25;q11.2) and
supporting consideration of this translocation as a marker of
biological aggressiveness.
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Introduction
Peripheral T-cell lymphoma (PTCL) collectively designates a
heterogeneous group of neoplasms derived frommature Tand
natural killer (NK) cells, altogether representing less than
15 % of all lymphomas [1]. These diseases have variable
clinical presentation (as predominantly disseminated/
leukemic, nodal, or extranodal diseases) and heterogeneous
pathological features, but with few exceptions, tend to pursue
an aggressive course, and have a poor outcome.
The genetic and molecular aberrations underlying T-cell
lymphomagenesis and the biological diversity of PTCL enti-
ties remain poorly characterized. Only two entities, namely,
anaplastic lymphoma kinase (ALK)-positive anaplastic large-
cell lymphoma (ALCL) and T-cell prolymphocytic leukemia
(PLL), are characterized by specific chromosomal transloca-
tions, involving ALK with NPM1 or other genes, and TCL1 or
MTCP1with TCRAD, respectively [1]. In the past years, a few
novel recurrent translocations have been identified in PTCLs,
mainly the t(5;9)(q33;q22) leading to SYK/ITK fusion found in
association with the so-called follicular variant of PTCL, not
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otherwise specified (NOS), translocations involving TP63 and
other p53-related genes, and recurrent translocations involv-
ing the IRF4 locus in chromosome region 6p25.3, with vari-
ous partner genes [2–5].
Here, we present the clinical and pathological features of a
PTCL, NOS harboring a t(6;14)(p25;q11.2) translocation,
juxtaposing the IRF4 and TCRAD loci.
Clinical history
A 64-year-old man with no significant previous medical his-
tory presented with complaints of asthenia, fever, arthralgia,
dyspnea at rest, and abdominal pain of recent onset (1–
2 weeks). At the time of admission, the patient was pale and
febrile (38 °C). Physical examination revealed palpable
splenomegaly, no peripheral lymphadenopathy, and no skin
lesion. Blood tests showed anemia (10.8 g Hb/dL), decreased
platelet count at 43×103/mm3, normal white cell absolute
(7.08×103/mm3) and differential counts, elevated C-reactive
protein (CRP) (159.4 mg/L, N=0–6), and increased lactate
dehydrogenase (LDH) levels (1,397 IU/L, N=240–480).
Liver tests were slightly abnormal with mild elevation of
bilirubin levels (11.3 mg/L, N=2.3–10) and elevated GGT
(253 IU/L, N=0–50), while transaminase levels were within
normal range. Renal function tests were normal. Serologies
for HIVandHCVwere negative. An extensive immunological
screening was performed in the search of an active infection,
but serologies only showed past immunization for Epstein-
Barr virus (EBV) and adenovirus.
Computed tomography (CT) of the chest and abdomen
confirmed a severe homogeneous splenomegaly and normal-
sized liver with probable mild steatosis, while no enlarged
lymphadenopathy was observed. Given high estimated risk of
spontaneous rupture of the spleen, the patient underwent
splenectomy on day 9 after admission. Liver needle biopsies
were obtained during the same operative procedure.
A diagnosis of PTCL, NOS was rendered (splenectomy,
see below). Altogether, including minimal involvement of the
liver and bone marrow, clinical staging was stage IVB, inter-
national prognostic index (IPI) score was 5, and the prognostic
index for T-cell lymphoma (PIT) score was 4. The patient was
treated with polychemotherapy (cyclophosphamide,
hydroxydoxorubicin, oncovin, prednisone, CHOP) at 3-
week intervals. After the fourth course of treatment, the pa-
tient developed fever and clinical investigations failed to
identify an infectious cause. A bone marrow biopsy revealed
diffuse lymphomatous infiltration, and PET showed general-
ized osteomedullary hyperfixation. The patient’s condition
progressively worsened, preventing administration of addi-
tional therapy, and he died 4 months after admission with
clinically progressive disease.
Pathological findings—methods and results
The spleen measured 25×13×11 cm and weighed 1,495 g. On
cut sections, the parenchyma displayed a homogeneous beefy
red appearance with multiple small subcapsular infarcts
(Fig. 1a). No lymph nodes were identified in the hilum.
Representative sections were routinely processed for paraffin
embedding after B-plus or formalin fixation, according to
standard procedures. Microscopic examination showed an
overall preserved architecture with pronounced expansion of
the red pulp and markedly atrophic white pulp (Fig. 1b–d). The
red pulp was overall congested with areas of red blood cell
extravasation and hemorrhage and was diffusely infiltrated by
atypical lymphoid cells featuring heterogeneous density, dis-
tributed mainly in the splenic cords, and sometimes also infil-
trating the walls of larger vessels. The lymphoid cells were
pleomorphic, medium- to large-sized. The smaller cells had
rather round nuclei, while the larger ones had irregular nuclear
contours, sometimes lobated nuclei, and variably prominent
nucleoli. A few cells had Reed-Sternberg-like features
(Fig. 1e). Mitoses were easily seen. There were no significant
infiltrate of eosinophils or histiocytes and no granulomas. Upon
immunostaining (by the use of a Ventana autostainer for all
antibodies, except for TCR gamma stained manually), CD20,
CD79a, and PAX5 essentially stained the small residual white
pulp nodules (Fig. 1d), while the lymphoid infiltrate in the red
pulp was diffusely CD3+ (Fig. 1c, f). The atypical lymphoid
cells were CD2+ CD3+ CD4+ CD5− CD7− CD8+/− CD10−
CD30− CD43+ CD45RA− CD45RO+ CD56− CD57−,
MUM1+, TCRbeta-F1+, and TCRgamma− and showed an
activated cytotoxic profile (TIA1+, granzymeB+) (Fig. 1f–l).
In situ hybridization for the EBV (using probes for EBV-
encoded RNAs, EBERs) was negative.
The liver biopsy (Fig. 1m) showed mild steatosis and
atypical medium to large lymphoid cells within the sinusoids
and in some portal tracts, which were positive for CD3 by
immunostaining (Fig. 1m, inset) and interpreted as hepatic
involvement by lymphoma.
Staging bone marrow aspirate and trephine biopsy were
performed. On HE sections, the marrow showed mildly
hypercellular trilinear hematopoiesis with complete matura-
tion, and no suspect lymphoid foci; immunostaining for CD3
Fig. 1 Pathological findings. a Gross appearance of a cut section of the
spleen after formalin fixation. b–d Low-power views (original
magnification, ×100) of the splenic parenchyma (b, H&E), showing
marked expansion of the red pulp by a population of CD3+ cells (c),
while the remnants of the white pulp were atrophic (d, CD20). e–l High-
power views (original magnifications, ×200 to ×400) of the splenic red
pulp, revealing atypical pleomorphic medium- to large-sized lymphoid
cells (e, H&E) with the following immunophenotype: CD3+ (f), CD5−
(g), TCRβF1+ (h), TIA1+ (i), MUM1+ (j), CD4+ (k), CD8+/− (l). m
High-power view (original magnification, ×400) of the liver biopsy,
showing intrasinusoidal atypical CD3+ lymphoid cells (H&E; inset,
CD3)
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highlighted scattered randomly distributed atypical lym-
phoid cells with irregular hyperchromatic nuclei, mostly
isolated or sometimes in small groups. No abnormal
lymphoid component was observed on the bone marrow
smears. Flow cytometry analysis of the aspirate per-
formed in the hematology laboratory showed a small
population of lymphoid cells (5 %) coexpressing CD3,
CD4, and CD8.
Conventional cytogenetic analysis performed on a spleen
tissue sample and on the bone marrow showed the same
abnormal clonal karyotype: 46,Y,add(X)(p22),t(6;14)(p25;
q11) in 3 of 4 metaphases from DSP30/IL2-stimulated spleen
cultures and 4 of 20 metaphases from classical bone marrow
cultures (Fig. 2a). The remaining metaphases showed a regu-
lar male karyotype 46,XY. Fluorescence in situ hybridization
(FISH) studies were performed with break-apart probes for
TCRAD (Abbott, Wiesbaden) and IRF4 [6]. A total of 37/100
and 30/100 nuclei counted showed a signal pattern indicating a
breakpoint in the TCRAD and IRF4 locus, respectively, demon-
strating that both loci were involved in the translocation
(Fig. 2b, c). Moreover, fusion of both loci was detected by a
double-color double-fusion assay in 30/100 nuclei using
breakpoint spanning probes for the TCRAD [7, 8] and IRF4 [6],
which confirmed juxtaposition of IRF4 and TCRAD (not shown).
A monoclonal rearrangement of the T-cell receptor gamma gene
(TCRG) was evidenced in the spleen and in the bone marrow,
with a clonal peak of identical size in both locations.
At progression, the bone marrow trephine biopsy revealed
fibro-edema and, despite overall low cellularity, a diffuse
infiltration by neoplastic lymphoid cells, with similar
A
B C
Fig. 2 Genetic findings. a QFQ-
banded karyogram of a
representative metaphase showing
the following karyotype:
46,Y,add(X)(p22),t(6;14)(p25;q11)
(arrows point at derivatives
der(6)t(6;14) and der(14)t(6;14)). b
Metaphase FISH with a TCRAD
break-apart probe showing a
colocalized signal for the intact
TCRAD locus on the normal
chromosome 14, an isolated red
signal on der(14)t(6;14), and an
isolated green signal on
der(6)t(6;14), indicating a
breakpoint in the TCRAD locus.
c Interphase FISH with an IRF4
break-apart probe showing a split
of the red and green signals in the
tumor cells indicating a breakpoint
in the IRF4 locus, in addition to one
intact copy of IRF4 (colocalized
red/green signal)
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morphology and immunophenotype (CD3+ CD5− CD4+
CD8+/−TIA1+) to those observed at diagnosis. No significant
intrasinusoidal pattern was noted.
Discussion
This is the third report of a case of PTCL, NOS associated
with a balanced t(6;14)(p25;q11) translocation involving the
IRF4 and TCRAD loci (Table 1). The first two cases reported
by Feldman et al. had similar clinicopathological features.
Both occurred in older men who presented with mild cytope-
nias and were found to have massive bone marrow involve-
ment by lymphoma, without peripheral blood involvement
a nd w i t hou t s i g n i f i c a n t l ymphadenopa t hy o r
hepatosplenomegaly, and both patients developed skin lesions
during the course of the disease. The lymphoma cells were
medium ormedium to large and, in both cases, had a cytotoxic
immunophenotype [3]. One of these patients was still alive at
4 months after diagnosis but was experiencing progressive
cutaneous disease, while the other was lost to follow-up.
Interestingly, the characteristics of the present case partly
overlap with those of the princeps cases, bringing support to
the notion that IRF4/TCRAD translocations might define a
rare subset of PTCL, NOS with distinct clinicopathologic
features. PTCLs harboring IRF4/TCRAD translocation are
derived from αβ T cells, feature pleomorphic medium- to
large-sized cell morphology, and are CD3+ CD5− (2/2 cases
tested) double positive for CD4 and CD8 (2/2 cases tested)
with a cytotoxic immunophenotype and negative for EBV.
Regarding the clinical presentation, while it was suggested
that bone marrow and skin involvement was typical of
t(6;14)(p25;q11.2)-positive PTCLs, the current case differs
by its predominantly splenic involvement and the lack of skin
lesions, while the bone marrow infiltration, albeit subtle at the
time of diagnosis, progressed under treatment. Interestingly,
common to all three cases is the lack of lymph node involve-
ment. The clinical course of our patient clearly reflects an
aggressive disease with rapid resistance to chemotherapy end-
ed with fatal outcome. Follow-up information for the cases
reported by Feldman et al. is unfortunately incomplete, but in
one of these cases, there is documented early disease progres-
sion under treatment. It can therefore be suspected that PTCLs
with IRF4/TCRAD translocations represent a particularly ag-
gressive subset of PTCLs.
While chromosomal breaks involving the TCR gene loci
occur recurrently in lymphoblastic T-cell neoplasms and in T-
cell prolymphocytic leukemia, their overall prevalence in
PTCL, NOS is extremely low [9]. Nevertheless, like typical
for T-PLL and T-ALL with TCRAD translocation, the present
case shows leukemic involvement. The rare TCR transloca-
tions (mostly involving the TCRAD locus) in PTCLyet remain
poorly understood, as the identity of the translocation
partner(s) has not been identified in most cases [7, 10, 11].
The poliovirus receptor-related 2 (PVRL2) has been cloned as
the partner gene of the TCRAD in the t(14;19)(q11;q13)
translocation and appears to be associated with overexpres-
sion of both PVRL2 and BCL3 messenger RNAs (mRNAs)
[12, 13].
In the case of the t(6;14)(p25;q11.2) translocation
discussed here, the question is which gene(s) in chromosome
band 6p25 is (are) deregulated by the juxtaposition to TCRAD.
MUM1, encoded by IRF4, is strongly expressed in the tumor
cells which might indicate IRF4 to be the target. However,
other rearrangements of the IRF4 locus at 6p25, unrelated to
TCRAD, have been identified in a substantial proportion of
ALK-negative ALCLs of the systemic or cutaneous type and
have been shown to involve the DUSP22 phosphatase gene
located more telomeric to IRF4 [14–16]. IRF4, also known as
multiple myeloma oncogene-1 (MUM1), is a transcription
factor acting as a regulator of normal lymphoid differentiation.
IRF4 expression in normal lymphoid cells is essentially re-
stricted to plasma cells, some B cells, and activated T lym-
phocytes, while its expression is deregulated in a variety of B-
and T-cell neoplasms, including a subset of plasma cell mye-
lomas and B cell lymphomas harboring structural modifica-
tions of the gene [6, 17]. ALK-negative ALCLs are usually
positive for MUM1 expression, irrespective of 6p25 rear-
rangements, and no significant difference in the IRF4
mRNA levels has been evidenced between translocated and
non-translocated cases [3]. In PTCL, NOS, MUM1 expres-
sion has generally been associated with a CD30+
immunophenotype. Given the consistently strong immunore-
activity for MUM1 antibodies in the three cases with IRF4/
TCRAD in the absence of CD30 expression, it seems reason-
able to infer that the translocation induced deregulated over-
expression of the IRF4 gene.
The splenic involvement by this t(6;14)(p25;q11.2)-
positive PTCL was characterized by diffuse red pulp
expansion, which is the most frequent pattern of splenic
involvement by mature NK/T-cell lymphoproliferations
[18]. In particular, differential diagnostic considerations
in this case include hepatosplenic T-cell lymphoma
(HSTL) and splenic involvement by T-cell large granular
lymphocytic leukemia (T-LGL), two entities with a cyto-
toxic phenotype. HSTL tends to occur in young adults
and is typically derived from γδ T cells, but αβ variants
have been described as well; more divergent from the case
reported here are the typically intrasinusoidal distribution
of the lymphoma cells, their monomorphic appearance,
and their non-activated cytotoxic phenotype in HSTL. In
addition, most cases of HSTL are associated with an
isochromosome 7q. T-LGL is a usually indolent lympho-
proliferation of CD3+ CD8+ cytotoxic T cells in older
individuals, comprising a circulating leukemic component
and a usually mild splenomegaly [1].
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In summary, the case reported here expands the clinical
spectrum of PTCLs harboring t(6;14)(p25;q11.2) and supports
consideration of this translocation as a marker for a subset of
clinically aggressive cytotoxic PTCL. Collection of additional
cases will be necessary to clarify their pathobiology. This
report also expands the differential diagnosis of cytotoxic
T-cell lymphomas with predominantly splenic involvement.
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